Advancements in Biomarkers for Early Diagnosis and Monitoring of Alzheimer's Disease

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by

cognitive decline, memory impairment, and behavioral changes. Early diagnosis and

monitoring of Alzheimer's disease are essential for effective treatment and management. Over

the years, significant advancements in the identification and utilization of biomarkers have

revolutionized the early detection and monitoring of AD. This paper explores the recent

progress in biomarkers for Alzheimer's disease, focusing on genetic, neuroimaging,

cerebrospinal fluid (CSF), and blood biomarkers. The research highlights the promising

potential of these biomarkers in diagnosing AD at earlier stages, monitoring disease

progression, and identifying novel therapeutic targets. Furthermore, the challenges and

limitations of using biomarkers in clinical settings are discussed, alongside future directions

for the continued development of AD biomarkers.